Nadeem H Bhanji1, Guy Chouinard, Howard C Margolese. 1. Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC, Canada. nadeem.bhanji@mail.mcgill.ca
Abstract
BACKGROUND: Several oral atypical antipsychotics are available for schizophrenia management. Besides positive and negative symptom control, they may improve cognition. Due to their limited availability as oral agents only, benefits are limited by noncompliance. METHODS: Using Medline and PsycINFO databases, literature was reviewed to address: (1) factors underlying medication noncompliance; (2) available evidence on efficacy of depot intramuscular (IM) typical antipsychotics; and (3) current knowledge of long-acting atypicals. RESULTS: Noncompliance remains high due to illness-, treatment-, and clinician-related factors. Compared to oral typicals, atypicals may improve compliance, even though noncompliance remains high. Depot IM typicals are efficacious (reduced relapses and rehospitalizations), but extrapyramidal symptoms are problematic. Available data on long-acting atypical risperidone suggest that it is safe and efficacious. CONCLUSION: Development of long-acting injectable atypical agents is warranted since noncompliance remains high. Future long-acting IM atypical trials should include outpatient functioning, and preferably be of longer duration to address cost-effectiveness.
BACKGROUND: Several oral atypical antipsychotics are available for schizophrenia management. Besides positive and negative symptom control, they may improve cognition. Due to their limited availability as oral agents only, benefits are limited by noncompliance. METHODS: Using Medline and PsycINFO databases, literature was reviewed to address: (1) factors underlying medication noncompliance; (2) available evidence on efficacy of depot intramuscular (IM) typical antipsychotics; and (3) current knowledge of long-acting atypicals. RESULTS: Noncompliance remains high due to illness-, treatment-, and clinician-related factors. Compared to oral typicals, atypicals may improve compliance, even though noncompliance remains high. Depot IM typicals are efficacious (reduced relapses and rehospitalizations), but extrapyramidal symptoms are problematic. Available data on long-acting atypical risperidone suggest that it is safe and efficacious. CONCLUSION: Development of long-acting injectable atypical agents is warranted since noncompliance remains high. Future long-acting IM atypical trials should include outpatient functioning, and preferably be of longer duration to address cost-effectiveness.
Authors: Mats O Magnusson; Mahesh N Samtani; Elodie L Plan; E Niclas Jonsson; Stefaan Rossenu; An Vermeulen; Alberto Russu Journal: Clin Pharmacokinet Date: 2017-04 Impact factor: 6.447
Authors: Gideon Sartorius; Carolyn Fennell; Sasa Spasevska; Leo Turner; Ann J Conway; David J Handelsman Journal: Asian J Androl Date: 2010-02-01 Impact factor: 3.285
Authors: Cheng-Kuo Wang; Wan-Yi Wang; Robert F Meyer; Yuling Liang; Karen I Winey; Steven J Siegel Journal: J Biomed Mater Res B Appl Biomater Date: 2010-05 Impact factor: 3.368
Authors: Marc M Baum; Irina Butkyavichene; Scott A Churchman; Gilbert Lopez; Christine S Miller; Thomas J Smith; John A Moss Journal: Int J Pharm Date: 2015-09-16 Impact factor: 5.875